Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections.(2) The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.(3,4) This article is protected by copyright. All rights reserved

Gisondi, P., Bianchi, L., Conti, A., Dapavo, P., Malagoli, P., Piaserico, S., et al. (2017). Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry. BRITISH JOURNAL OF DERMATOLOGY, 177(6), 325-326 [10.1111/bjd.15659].

Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.

BIANCHI, LUCA;
2017

Abstract

Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections.(2) The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.(3,4) This article is protected by copyright. All rights reserved
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Gisondi, P., Bianchi, L., Conti, A., Dapavo, P., Malagoli, P., Piaserico, S., et al. (2017). Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry. BRITISH JOURNAL OF DERMATOLOGY, 177(6), 325-326 [10.1111/bjd.15659].
Gisondi, P; Bianchi, L; Conti, A; Dapavo, P; Malagoli, P; Piaserico, S; Savoia, F; Prignano, F; Girolomoni, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
gisondi.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 77.99 kB
Formato Adobe PDF
77.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/185029
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact